Commonly reported side effects of topotecan include: febrile neutropenia, sepsis, infection, abdominal pain, alopecia, anemia, asthenia, constipation, dyspnea, fatigue, fever, headache, leukopenia, nausea, neutropenia, stomatitis, thrombocytopenia, vomiting, granulocytopenia, diarrhea, and anorexia. Other side effects include: febrile neutropenia, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, intestinal obstruction, pain, and paresthesia.  See below for a comprehensive list of adverse effects.
Applies to topotecan: oral capsule
Other dosage forms:
As well as its needed effects, topotecan may cause unwanted side effects that require medical attention. 
If any of the following side effects occur while taking topotecan, check with your doctor immediately:
Some topotecan side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:


Applies to topotecan: intravenous powder for injection, intravenous solution, oral capsule
The most common adverse events were hematologic: neutropenia, leukopenia, anemia, and thrombocytopenia.[Ref]
Very common (10% or more): Neutropenia (up to 97%), leukopenia (97%), anemia (up to 94%), thrombocytopenia (up to 74%), pyrexia/grade 4 neutropenia (28%), febrile neutropenia (28%), hemorrhage (15%)Common (1% to 10%): Pancytopenia, coagulation adverse eventPostmarketing reports: Severe bleeding (in association with thrombocytopenia)[Ref]
Very common (10% or more): Nausea (64%), other gastrointestinal adverse event (63%), vomiting (45%), diarrhea (32%), constipation (29%), abdominal pain (22%), stomatitis (18%)Common (1% to 10%): Abdominal pain, intestinal obstruction, dyspepsiaFrequency not reported: Neutropenic colitisPostmarketing reports: Abdominal pain potentially associated with neutropenic colitis[Ref]
Rash includes pruritus, rash erythematous, urticaria, dermatitis, bullous eruption, and maculopapular rash.[Ref]
Very common (10% or more): Alopecia (49%), dermatologic adverse reaction (48%), rash (16%)Common (1% to 10%): PruritusFrequency not reported: UrticariaPostmarketing reports: Angioedema, severe dermatitis, severe pruritus[Ref]
Very common (10% or more): Sepsis or pyrexia/infection with neutropenia (43%), infection-febrile neutropenia (28%), infection (27%)Common (1% to 10%): Pneumonia, allergy-immunology adverse event, pharyngitis, rhinitis, sepsis
Pain includes abdominal pain or cramping, arthralgia, bone pain, chest pain (non-cardiac and non-pleuritic), dysmenorrhea, dyspareunia, earache, headache, hepatic pain, myalgia, neuropathic pain, pain due to radiation, pelvic pain, pleuritic pain, rectal or perirectal pain, tumor pain, body pain, back pain, and skeletal pain."Constitutional" is a composite term that includes fatigue (lethargy, malaise, asthenia), fever (in the absence of neutropenia), rigors, chills, sweating, and weight gain or loss.
Very common (10% or more): Constitutional (69%), pain (up to 59%), fatigue (29%), pyrexia (28%), asthenia (25%), mucositis (14%)Common (1% to 10%): Treatment related death, malaise
Very common (10% or more): Dyspnea (22%), pulmonary adverse event (17%), coughing (15%)Common (1% to 10%): Epistaxis, respiratory disorderRare (less than 0.1%): Interstitial lung diseasePostmarketing reports: Fatal interstitial lung disease[Ref]
Very common (10% or more): Hepatic adverse event (24%)Common (1% to 10%): Transient elevations in hepatic enzymes, hyperbilirubinemia, elevated ALT, elevated AST[Ref]
Very common (10% or more): Non-neuropathy neurologic adverse event (35%), headache (18%)Common (1% to 10%): Paresthesia, neuropathy, dizzinessUncommon (0.1% to 1%): Hypoesthesia, peripheral neuropathy, paresis[Ref]
Very common (10% or more): Cardiovascular adverse event (25%)[Ref]
Very common (10% or more): Metabolic-laboratory adverse event (39%), anorexia (19%)Frequency not reported: Dehydration
Very common (10% or more): Musculoskeletal adverse event (14%)[Ref]
Common (1% to 10%): Hypersensitivity (including rash)Postmarketing reports: Allergic manifestations, anaphylactoid reactions[Ref]
Very common (10% or more): Genitourinary adverse event (36%)Common (1% to 10%): Sexual reproduction function adverse event[Ref]
Rare (less than 0.1%): ExtravasationPostmarketing reports: Inadvertent extravasation
Common (1% to 10%): Endocrine adverse event
Common (1% to 10%): Ocular-visual adverse event
1. Betcher DL, Burnham N "Topotecan." J Pediatr Oncol Nurs 9 (1992): 31-2
2. Lilenbaum RC, Ratain MJ, Miller AA, Hargis JB, Hollis DR, Rosner GL, O'Brien SM, Brewster L, Green MR, Schilsky RL "Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study." J Clin Oncol 13 (1995): 2230-7
3. Sabiers JH, Berger NA, Berger SJ, Haaga JR, Hoppel CL, Willson JK "Phase I trial of topotecan administered as a 72-hr infusion (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a25411993
4. Hochster H, Liebes L, Speyer J, Sorich J, Taubes B, Oratz R, Wernz J, Chachoua A, Raphael B, Vinci RZ, et al "Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen." J Clin Oncol 12 (1994): 553-9
5. Kantarjian HM, Beran M, Ellis A, Zwelling L, O'Brien S, Cazenave L, Koller C, Rios MB, Plunkett W, Keating MJ, et al "Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia." Blood 81 (1993): 1146-51
6. "Product Information. Hycamtin (topotecan)." SmithKline Beecham, Philadelphia, PA. 
7. Eckardt J, Burris H, Kuhn J, Smith S, Rodriguez G, Weiss G, Smith L, Shaffer D, Johnson R, Von Hoff D "PHASE I AND PHARMACOKINETIC TRIAL OF CONTINUOUS INFUSION TOPOTECAN IN PATIENTS WITH REFRACTORY SOLID TUMORS (MEETING ABSTRACT)." Proc Annu Meet Am Soc Clin Oncol 11 (1992): a3731992
8. Saltz L, Sirott M, Young C, et al. "Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor." J Natl Cancer Inst 85 (1993): 1499-507
9. van Warmerdam LJ, ten Bokkel Huinink WW, Rodenhuis S, Koier I, Davies BE, Rosing H, Maes RA, Beijnen JH "Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion." J Clin Oncol 13 (1995): 1768-76
10. Stewart CF, Baker SD, Heideman RL, Jones D, Crom WR, Pratt CB "Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity." J Clin Oncol 12 (1994): 1946-54
11. Wall J, Burris H, Rodriguez G, Brown T, Weiss G, Kuhn J, Brown J, Johnson R, Friedman C, Mann W, et al "PHASE I TRIAL OF TOPOTECAN (SK AND F 104864) IN PATIENTS WITH REFRACTORY SOLID TUMORS (MEETING ABSTRACT)." Proc Annu Meet Am Soc Clin Oncol 10 (1991): a2611991
12. Janik J, Miller L, Smith J, Kopp W, Alvord G, Gause B, Curti B, Urba WJ, Longo DL "Prechemotherapy granulocyte-macrophage colony stimulating factor (GM- CSF) prevents topotecan-induced neutropenia (Meeting abstract)." Proc Annu Meet Am Soc Clin Oncol 12 (1993): a15071993
13. Miller AA, Hargis JB, Lilenbaum RC, Fields SZ, Rosner GL, Schilsky RL "Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study." J Clin Oncol 12 (1994): 2743-50
14. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH, et al "Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor." J Clin Oncol 10 (1992): 647-56
15. Haas NB, LaCreta FP, Walczak J, Hudes GR, Brennan J, Ozols RF, O'Dwyer PJ "PHASE I/PHARMACOKINETIC TRIAL OF TOPOTECAN ON A WEEKLY 24-HOUR INFUSION SCHEDULE (MEETING ABSTRACT)." Proc Annu Meet Am Assoc Cancer Res 33 (1992): a31281992
16. O'Brien S, Kantarjian H, Ellis A, Zwelling L, Estey E, Keating M "Topotecan in chronic lymphocytic leukemia." Cancer 75 (1995): 1104-8
17. Pratt CB, Stewart C, Santana VM, Bowman L, Furman W, Ochs J, Marina N, Kuttesch JF, Heideman R, Sandlund JT, et al "Phase I study of topotecan for pediatric patients with malignant solid tumors." J Clin Oncol 12 (1994): 539-43
18. Rowinsky EK, Adjei A, Donehower RC, Gore SD, Jones RJ, Burke PJ, Cheng YC, Grochow LB, Kaufmann SH "Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia." J Clin Oncol 12 (1994): 2193-203
19. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0
20. Edgerton CC,  Gilman M,  Roth BJ "Topotecan-induced bronchiolitis." South Med J 97 (2004): 699-701
It is possible that some side effects of topotecan may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.
intravenous powder for solution, intravenous solution

Black, tarry stools
bleeding gums
blood in the urine or stools
chest pain
chills
cough
fever
lower back or side pain
painful or difficult urination
pale skin
pinpoint red spots on the skin
shortness of breath
sore throat
sores, ulcers, or white spots on the lips or in the mouth
swollen glands
troubled breathing with exertion
unusual bleeding or bruising
unusual tiredness or weakness


Diarrhea
hair loss or thinning of the hair
lack or loss of strength
loss of appetite
nausea
vomiting
weight loss

